Trials / Unknown
UnknownNCT05188911
Analysis of Next Generation PET and Liquid Biopsy to Monitor mCRPC Treated With Abiraterone: ANGELA Trial
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 30 (estimated)
- Sponsor
- Fudan University · Academic / Other
- Sex
- Male
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
By incorporating dual-tracer PET/CT (PSMA and FDG) and ctDNA, we aimed to evaluate lesion heterogeneity and genomic change of mCRPC patients receiving novel hormonal therapy. The relationship between treatment response and different molecular characterization, as well as imaging features would also be evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Abiraterone | Patients would be treated with 1000mg abiraterone qd. |
| DRUG | Prednisone | Patients would be treated with 5mg prednisone bid. |
| DRUG | Androgen deprivation therapy | Patients would get medical or surgical castration. |
Timeline
- Start date
- 2020-07-15
- Primary completion
- 2022-07-15
- Completion
- 2022-07-15
- First posted
- 2022-01-12
- Last updated
- 2022-01-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05188911. Inclusion in this directory is not an endorsement.